MicroRNA-130a modulates a radiosensitivity of rectal cancer by targeting SOX4

Area of Science:

• Molecular Oncology
• Cancer Therapeutics
• Radiotherapy Research

Background:

• Radioresistance is a significant obstacle in advanced rectal cancer treatment, limiting therapeutic efficacy.
• Understanding the molecular mechanisms underlying radioresistance is crucial for improving patient survival rates.
• Novel molecular targets are needed to enhance the sensitivity of rectal cancer cells to radiation therapy.

Purpose of the Study:

• To identify novel molecular targets that modulate the radiosensitivity of human rectal cancer cells.
• To elucidate the role and mechanism of microRNA-310a (miR-130a) in rectal cancer radioresistance.

Main Methods:

• Small RNA sequencing was performed on human rectal cancer cell lines.
• Bioinformatics analysis was used to identify candidate microRNAs.
• Functional studies involved miR-130a overexpression, assessment of epithelial-mesenchymal transition, DNA damage repair inhibition, and SOX4 target validation.

Main Results:

• MicroRNA-310a (miR-130a) was significantly upregulated in radiosensitive rectal cancer cells.
• Overexpression of miR-130a enhanced rectal cancer cell radiosensitivity by reversing epithelial-mesenchymal transition and inhibiting DNA damage repair.
• SOX4 was identified as a direct target of miR-130a, and its overexpression counteracted the radiosensitizing effects of miR-130a.

Conclusions:

• MicroRNA-310a (miR-130a) acts as a radiosensitizer in rectal cancer, promoting cell death after irradiation.
• miR-130a represents a potential therapeutic target for overcoming radioresistance in rectal cancer.
• miR-130a may serve as a preoperative prognostic marker for radiotherapy response in rectal cancer patients.